Impairment of assets held for sale
Bristol-Myers Squibb Impairment of assets held for sale decreased by 29.5% to $412.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8140.0%, from $5.00M to $412.00M. Over 4 years (FY 2021 to FY 2025), Impairment of assets held for sale shows relatively stable performance with a -2.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase suggests poor asset valuation or declining market demand for non-core business units, while a decrease indicates stable asset values or successful divestiture execution.
Detailed definition
This represents non-cash charges recognized when the carrying value of long-lived assets held for sale exceeds their fai...
Peer comparison
Common in large pharmaceutical companies undergoing portfolio restructuring or M&A integration.
operating_impairment_of_long_lived_assets_to_be_disposed_ofHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $240.00M | $613.00M | $15.00M | $41.00M | $42.00M | $61.00M | $35.00M | $20.00M | $47.00M | $159.00M | $29.00M | $1.00M | $870.00M | $139.00M | $1.95B | $5.00M | $313.00M | $196.00M | $584.00M | $412.00M |
| QoQ Change | — | +155.4% | -97.6% | +173.3% | +2.4% | +45.2% | -42.6% | -42.9% | +135.0% | +238.3% | -81.8% | -96.6% | >999% | -84.0% | >999% | -99.7% | >999% | -37.4% | +198.0% | -29.5% |
| YoY Change | — | — | — | — | -82.5% | -90.0% | +133.3% | -51.2% | +11.9% | +160.7% | -17.1% | -95.0% | >999% | -12.6% | >999% | +400.0% | -64.0% | +41.0% | -70.1% | >999% |
Impairment of assets held for sale at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's impairment of assets held for sale?
- Bristol-Myers Squibb (BMY) reported impairment of assets held for sale of $412.00M in Q1 2026.
- How has Bristol-Myers Squibb's impairment of assets held for sale changed year-over-year?
- Bristol-Myers Squibb's impairment of assets held for sale increased by 8140.0% year-over-year, from $5.00M to $412.00M.
- What is the long-term trend for Bristol-Myers Squibb's impairment of assets held for sale?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's impairment of assets held for sale has grown at a -2.3% compound annual growth rate (CAGR), from $1.21B to $1.10B.
- What does impairment of assets held for sale mean?
- Non-cash losses recorded when assets intended for sale are worth less than their current book value.